Gilead Sciences, Inc. announced a private placement that it has received $210,000,000 in funding on March 4, 2024. The transaction will include participation from returning investor, Abingworth LLP.
Market Closed -
Other stock markets
|
Pre-market 14:04:34 | |||
64.92 USD | -0.82% | 65.3 | +0.59% |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.86% | 80.95B | |
+32.95% | 698B | |
+26.51% | 568B | |
-4.97% | 358B | |
+18.83% | 328B | |
+3.54% | 283B | |
+15.78% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+6.70% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP